SHANGHAI YIZHONG(688091.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
SHANGHAI YIZHONG
688091.SH
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.
2.788 T
688091.SHMarket value -Rank by Market Cap -/-

Financial Score

21/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking20/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.74%C
    • Profit Margin20.94%A
    • Gross Margin85.26%A
  • Growth ScoreA
    • Revenue YoY84.92%A
    • Net Profit YoY949.64%A
    • Total Assets YoY5.40%C
    • Net Assets YoY1.81%C
  • Cash ScoreB
    • Cash Flow Margin0.00%D
    • OCF YoY84.92%A
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio6.31%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The A-share innovative drug sector surged in the afternoon, with WECOME rising over 15%, Frontier Biotechnologies and SHANGHAI YIZHONG rising over 10%, and JLPC, Hongbo Pharmaceutical, Genrix Bio, and Chengda Pharmaceutical following suit

    Wallstreetcn·
    SZ
    300878
    -3.18%
    SH
    688221
    -1.65%
    SH
    600513
    -0.87%
    Wallstreetcn·
    SZ
    300878
    -3.18%
    SH
    688221
    -1.65%
    SH
    600513
    -0.87%

    HuaYuan Securities: The potential of PD1/VEGF/IL-2 is promising, insisting on innovative drugs as the main line for the whole year

    Zhitong·
    SH
    688091
    -4.35%
    Zhitong·
    SH
    688091
    -4.35%

    Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

    Zhitong·
    SH
    603127
    +10.01%
    HK
    06127
    +5.35%
    SZ
    002262
    +1.42%
    Zhitong·
    SH
    603127
    +10.01%
    HK
    06127
    +5.35%
    SZ
    002262
    +1.42%

    SHANGHAI YIZHONG plans to repurchase shares for 30 million to 35 million yuan

    Zhitong·
    SH
    688091
    -4.35%
    Zhitong·
    SH
    688091
    -4.35%

    SHANGHAI YIZHONG: The chairman proposed to repurchase shares worth 30 million to 35 million yuan

    Zhitong·
    SH
    688091
    -4.35%
    Zhitong·
    SH
    688091
    -4.35%
    © 2026 Longbridge｜Disclaimer